Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891407 | 0.84 | SMN1; SMN2 (0.61) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL805356 | 0.84 | MAPT (0.61) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL11790 | 0.83 | SMN1; SMN2 (0.56) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL9011867 | 0.82 | SMN1; SMN2 (0.59) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL148506 | 0.82 | TSHR (0.55) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL12428 | 0.81 | SMN1; SMN2 (0.54) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2096772 | 0.80 | KMT2A (0.53) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2096769 | 0.80 | L3MBTL1 (0.49) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL13761018 | 0.80 | ESR1 (0.47) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL293026 | 0.80 | SMN1; SMN2 (0.49) | KDM4EL3MBTL1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102325659-B | Novel color-forming compounds and use thereof in imaging members and methods | ZINK IMAGING INC | 2015-04-01 | — | — | CN | claimed |
| US-8426115-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | claimed |
| US-20110033803-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | claimed |
| US-20100159392-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | claimed |
| US-5362902-A | Diuretics and treatment of cardiovascular disorders | PFIZER INC. (US) | 1994-11-08 | — | — | US | claimed |
| US-20230200208-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10011772-B2 | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-9976086-B2 | Liquid crystal aligning agent containing polyimide precursor having thermally-leaving group and/or polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1345943-B1 | INHIBITORS OF PAPILLOMA VIRUS | BOEHRINGER INGELHEIM CA LTD (CA) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005082866-A2 | SUBSTITUTED 1, 2, 4- TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | KDM4E 2034/4885L3MBTL1 3167/4885MAPT 2596/4885 |
| US-20230200208-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | CRY1, PPOX, ODC1 | KDM4E 1344/4885L3MBTL1 39/4885MAPT 1168/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | KDM4E 2603/4885L3MBTL1 3011/4885MAPT 2629/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | KDM4E 3178/4885L3MBTL1 3174/4885MAPT 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.